Edwards Lifesciences Has Everything Investors Want Except Value
Edwards Lifesciences is recognized as a high-quality company with significant growth potential, yet its stock is considered overvalued. The company reported strong first-quarter results and raised its guidance for 2026, but its current trading price limits potential upside. Analysts suggest a 'Hold' rating until the stock price becomes more attractive for investment.
- ▪Edwards Lifesciences has a wide economic moat and accelerating growth.
- ▪The stock is currently trading at nearly 47 times earnings and free cash flow.
- ▪Management anticipates 9-11% sales growth and improving margins for 2026.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909180-edwards-lifesciences-has-everything-investors-want-except-value"},"author":{"@type":"Person","name":"Daniel Schönberger","url":"https://seekingalpha.com/author/daniel-schonberger"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
